PROVENTION BIO INC (PRVB) Stock Price, Forecast & Analysis
NASDAQ:PRVB • US74374N1028
PRVB Key Statistics, Chart & Performance
The current stock price of PRVB is 24.98 USD. In the past month the price increased by 4.26%. In the past year, price increased by 456.35%.
PRVB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRVB. When comparing the yearly performance of all stocks, PRVB is one of the better performing stocks in the market, outperforming 99.85% of all stocks.
PRVB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRVB. PRVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRVB Financial Highlights
Over the last trailing twelve months PRVB reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.19 |
PRVB Forecast & Estimates
12 analysts have analysed PRVB and the average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98.
For the next year, analysts expect an EPS growth of -18.96% and a revenue growth 372.61% for PRVB
PRVB Ownership
PRVB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.45 | 972.635B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 590.688B | ||
| MRK | MERCK & CO. INC. | 22.05 | 303.948B | ||
| PFE | PFIZER INC | 9.02 | 154.026B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.04 | 124.791B | ||
| ZTS | ZOETIS INC | 18.89 | 56.827B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.062B | ||
| VTRS | VIATRIS INC | 6.03 | 18.521B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.05 | 13.336B | ||
| AXSM | AXSOME THERAPEUTICS INC | 199.27 | 8.278B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRVB
Company Profile
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 174 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
Company Info
PROVENTION BIO INC
55 Broad Street, 2Nd Floor
Red Bank New Jersey NEW JERSEY 07701 US
CEO: Ashleigh Palmer
Employees: 174
Phone: 19084289136.0
PROVENTION BIO INC / PRVB FAQ
What does PRVB do?
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 174 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
What is the stock price of PROVENTION BIO INC today?
The current stock price of PRVB is 24.98 USD. The price increased by 3.1% in the last trading session.
Does PRVB stock pay dividends?
PRVB does not pay a dividend.
What is the ChartMill rating of PROVENTION BIO INC stock?
PRVB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about PROVENTION BIO INC (PRVB) stock?
12 analysts have analysed PRVB and the average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98.
Can you provide the market cap for PROVENTION BIO INC?
PROVENTION BIO INC (PRVB) has a market capitalization of 2.37B USD. This makes PRVB a Mid Cap stock.
When does PROVENTION BIO INC (PRVB) report earnings?
PROVENTION BIO INC (PRVB) will report earnings on 2023-08-02, before the market open.